Neuphoria Therapeutics (NASDAQ:NEUP) Trading Up 17.7% – Still a Buy?

Neuphoria Therapeutics Inc. (NASDAQ:NEUP)’s stock price traded up 17.7% during mid-day trading on Thursday . The stock traded as high as $4.20 and last traded at $3.92. Approximately 7,610,379 shares traded hands during mid-day trading, an increase of 8,538% from the average session volume of 88,104 shares. The stock had previously closed at $3.33.

Analyst Ratings Changes

A number of equities research analysts have weighed in on NEUP shares. HC Wainwright lowered Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 15th. Wall Street Zen upgraded Neuphoria Therapeutics to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research note on Monday, June 1st. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $21.00.

Neuphoria Therapeutics Trading Down 7.1%

The firm has a market cap of $19.66 million, a P/E ratio of -0.33 and a beta of 0.74. The firm has a 50-day simple moving average of $4.29 and a 200-day simple moving average of $4.39.

Neuphoria Therapeutics (NASDAQ:NEUP) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.47. Research analysts predict that Neuphoria Therapeutics Inc. will post -4.07 earnings per share for the current fiscal year.

Institutional Trading of Neuphoria Therapeutics

Several hedge funds have recently modified their holdings of NEUP. Commonwealth Equity Services LLC purchased a new position in shares of Neuphoria Therapeutics in the 4th quarter worth approximately $43,000. XTX Topco Ltd purchased a new stake in Neuphoria Therapeutics during the fourth quarter valued at approximately $47,000. Persistent Asset Partners Ltd lifted its position in Neuphoria Therapeutics by 173.1% during the fourth quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock valued at $52,000 after acquiring an additional 8,495 shares during the last quarter. Boothbay Fund Management LLC acquired a new stake in Neuphoria Therapeutics in the fourth quarter valued at approximately $54,000. Finally, Bridgeway Capital Management LLC acquired a new stake in Neuphoria Therapeutics in the fourth quarter valued at approximately $57,000. 15.90% of the stock is owned by hedge funds and other institutional investors.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.